United States - English - NLM (National Library of Medicine)

octapharma usa inc - human immunoglobulin g (unii: 66y330cjhs) (human immunoglobulin g - unii:66y330cjhs) - cutaquig (immune globulin subcutaneous (human) - hipp) is a 16.5% immune globulin solution for subcutaneous infusion (igsc), indicated as replacement therapy for primary humoral immunodeficiency (pi) in adults and pediatric patients 2 years of age and older. this includes, but is not limited to, common variable immunodeficiency (cvid), x-linked agammaglobulinemia, congenital agammaglobulinemia, wiskott-aldrich syndrome, and severe combined immunodeficiencies. cutaquig is contraindicated: - in patients who have had an anaphylactic or severe systemic reaction to the subcutaneous administration of human immune globulin or to any of the components of cutaquig such as polysorbate 80. - in iga-deficient patients with antibodies against iga and a history of hypersensitivity to human globulin treatment. risk summary no human data are available to indicate the presence or absence of drug-associated risk. animal reproduction studies have not been conducted with cutaquig. it is not known whether cutaquig can cause fet

United States - English - NLM (National Library of Medicine)

pfizer laboratories div pfizer inc - human immunoglobulin g (unii: 66y330cjhs) (human immunoglobulin g - unii:66y330cjhs) - cutaquig (immune globulin subcutaneous (human) - hipp) is a 16.5% immune globulin solution for subcutaneous infusion (igsc), indicated as replacement therapy for primary humoral immunodeficiency (pi) in adults and pediatric patients 2 years of age and older. this includes, but is not limited to, common variable immunodeficiency (cvid), x-linked agammaglobulinemia, congenital agammaglobulinemia, wiskott-aldrich syndrome, and severe combined immunodeficiencies. cutaquig is contraindicated: - in patients who have had an anaphylactic or severe systemic reaction to the subcutaneous administration of human immune globulin or to any of the components of cutaquig such as polysorbate 80. - in iga-deficient patients with antibodies against iga and a history of hypersensitivity to human globulin treatment. risk summary no human data are available to indicate the presence or absence of drug-associated risk. animal reproduction studies have not been conducted with cutaquig. it is not known whether cutaquig can cause fet

Malta - English - Medicines Authority

octapharma (ip) sprl alle de la recherche 65, 1070 (anderlecht), belgium - human normal, immunoglobulin - solution for injection - human normal immunoglobulin 165 mg - immune sera and immunoglobulins

Ireland - English - HPRA (Health Products Regulatory Authority)

octapharma (ip) sprl - human normal immunoglobulin - solution for injection - 165 milligram(s)/millilitre - immunoglobulins, normal human; immunoglobulins, normal human, for extravascular adm.

Canada - English - Health Canada

octapharma pharmazeutika produktionsges m b h - immunoglobulin g (human) - solution - 1g - immunoglobulin g (human) 1g - serums

Canada - English - Health Canada

octapharma pharmazeutika produktionsges m b h - immunoglobulin g (human) - solution - 2g - immunoglobulin g (human) 2g - serums

Canada - English - Health Canada

octapharma pharmazeutika produktionsges m b h - immunoglobulin g (human) - solution - 4g - immunoglobulin g (human) 4g - serums

Canada - English - Health Canada

octapharma pharmazeutika produktionsges m b h - immunoglobulin g (human) - solution - 8g - immunoglobulin g (human) 8g - serums

Canada - English - Health Canada

octapharma pharmazeutika produktionsges m b h - immunoglobulin g (human) - solution - 1.65g - immunoglobulin g (human) 1.65g - serums

Canada - English - Health Canada

octapharma pharmazeutika produktionsges m b h - immunoglobulin g (human) - solution - 3.3g - immunoglobulin g (human) 3.3g - serums